PSA - Based early detection of prostate cancer;PSA - Fruherkennung des prostatakarzinoms

Urologe - Ausgabe A

Volumn 39, Issue 1, 2000, Pages 22-26

  Luboldt, H J ^a   Rubben H ^b  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b NONE

Author keywords

Early detection; Prostate cancer; Prostate specific antigen

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

CANCER MORTALITY; CANCER SCREENING; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; GERMANY; PHYSICAL EXAMINATION; PROSTATE CANCER; REVIEW; TUMOR BIOPSY; BLOOD; DIFFERENTIAL DIAGNOSIS; HUMAN; MALE; MASS SCREENING; PREDICTION AND FORECASTING; PROSTATE HYPERTROPHY; PROSTATE TUMOR; REFERENCE VALUE;

DIAGNOSIS, DIFFERENTIAL; HUMANS; MALE; MASS SCREENING; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REFERENCE VALUES; TUMOR MARKERS, BIOLOGICAL;

EID: 0342858867     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001200050005     Document Type: Review

References (33)

1. Altwein J (1998) Diagnostik und Stadieneinteilung. In: Rübben H (Hrsg) Uroonkolgie (2. Aufl., Sonderpublikation, Kapitel 6), S 67-94. Springer, Berlin Heidelberg New York
2. Beduschi M, Oesterling J (1997) Prostate-specific antigen density. In: Oesterling J (ed) Urol Clin North Am, 323-332. Saunders, Philadelphia
3. Benson M, Whang I, Olsson C (1992) Use of prostate specific antigen density to enhance predictive value of intermediate levels of serum prostate specific antigen. J Urol 147: 817-821
4. Carter H, Pearson J (1993) PSA velocity for the diagnosis of early prostate cancer. Urol Clin North Am 20: 665-670
5. Carter H, Pearson J (1997) Prostate-specific antigen velocity and repeated measures of prostate-specific antigen. Urol Clin North Am 24: 333-338
6. Carter H, Pearson J, Metter E, Brant L, Chan D, Andres R, Fozard J, Walsh P (1992) Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 267: 2215-2220
7. Catalona W, Richie J, Ahmann F, Hudson M, Scardino P, Flanigan R, deKernion J, Ratliff T, Kavoussi L, Dalkin B, Waters W, MacFarlane M, Southwick P (1994) Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 151: 1283-1290
8. Catalona W, Smith D, Ornstein D (1997) Prostate cancer detection in men with serum PSA concentration of 2.6 to 4.0 ng/ml and Benign Prostate Examination. JAMA 277: 1452-1455
9. Catalona WJ (1996) Clinical utility of measurements of free and total prostate-specific antigen (PSA): a review. Prostate [Suppl] 7: 64-69
10. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, Richie JP, deKernion JB, Walsh PC, Scardino PT, Lange PH, Subong ENP, Parson EP, Gasior GH, Loveland KG, Southwick PC (1998) Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease. JAMA 279: 1542-1547
11. Ellis W, Brawer M (1994) The significance of isoechoic prostatic carcinoma. J Urol 152: 2304-2307
12. Hoedemaeker R, Rietbergen J, Kranse R, van der Kwast T, Schröder FH (1997) Comparison of pathological characteristics of T1 c and non-T1 c cancers detected in a population-based screening study, the European Randomized Study of Screening for Prostate Cancer. World J Urol 15: 339-345
13. Hogde K, McNeal J, Terris M, Stamey T (1989) Random systematic versus directed ultrasound guided core biopsies of the prostate. J Urol 142: 74-80
14. Huland H, Hammerer P, Henke R, Huland E (1996) Preoperative prediction of tumor heterogeneity and recurrence after radical prostatectomy for localized prostatic carcinoma with digital rectal examination, prostate specific antigen and the results of 6 systematic biopsies. J Urol 155(4): 1344-1347
15. Kirby R, Kirny M, Feneley M, McNicholas T, McLean A, Webb J (1994) Screening for carcinoma of the prostate: a GP based study. Br J Urol 74: 64-71
16. Labrie F, Candas B, Dupont A, Cusan L, Gomez JL, Suburu RE, Diamond P, Lévesque J, Belanger A (1999) Sreening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 38: 83-91
17. Luboldt H-J, Altwein JE, Bichler K-H, Czaja D, Hüsing J, Fornara P, Jöckel K-H, Lübben G, Schalkhäuser K, Weißbach L, Wirth M, Rübben H (1999) Früherkennung des Prostatakarzinoms - Erste Ergebnisse einer prospektiven multizentrischen Studie in Deutschland. Urologe [A] 38: 114-123
18. Mettlin C, Murphy G (1998) Why is the prostate cancer death rate declinig in the United States? Cancer 82(2): 249-251
19. Oesterling J, Jacobsen S, Chute C, Guess H, Girman C, Panser L, Lieber M (1993) Serum prostate-specific antigen in a community-based population of healthy men. JAMA 270: 860-864
20. Ohori M, Wheeler T, Dunn J, Stamey T, Scardino P (1994) The pathological features and prognosis of prostate cancers detectable with current diagnostic tests. J Urol 152: 1714-1720
21. Rietbergen J, Boeken Kruger A, Hoedemaker R, Bangma C, Kirkels W, Schroeder FH (1998) Repeat screening for prostate cancer after 1-year followup in 984 biopsied men: clinical and pathological features of detected cancer. J Urol 160: 2121-2125
22. Rietbergen J, Kranse R, Kirkels W, de Koning H, Schröder FH (1997) Evaluation of prostate-specific antigen, digital rectal examination and transrectal ultrasonography in population-based screening for prostate cancer: improving the efficiency of early detection. Br J Urol 79: 57-63
23. Schmid H, Altwein JE, Faul P, Wirth M (1999) Screening und Früherkennung des Prostatakarzinoms. Dtsch Ärztebl 96 12: A-772-777
24. Schroeder FH, Bangma C (1997) The European randomized study of screening for prostate cancer (ERSPC). Br J Urol [Suppl 1] 79: 68-71 (Suppl.1)
25. Schroeder FH (1995) Screening, early detection, and treatment of prostate cancer: a european view. Urology [Suppl] 46: 62-70
26. Schwartz F, Robra B (1996) Stand und Perspektiven der Forschung zur Krebsfrüherkennung. In: Schwartz F, Badura B, Brecht J, Hofmann W, Jöckel K, Trojan A (Hrsg) Public health. Springer, Berlin Heidelberg New York
27. Seaman E, Whang M, Olsson C (1993) PSA density (PSAD): role in patient evaluation and management. Urol Clin North Am 20: 653-657
28. Semjonow A, Brandt B, Oberpennig F, Hertle L (1995) Unterschiedliche Bestimmungsverfahren erschweren die Interpretation des prostataspezifischen Antigens. Urologe [A] 34: 303-315
29. Sokoll L, Chan D (1997) Prostate-specific antigen. In: Oesterling J (ed) Urol Clin North Am, 253-259. Saunders, Philadelphia
30. Statistisches Bundesamt (1996) Todesursachen in Deutschland. Fachserie 12, Reihe 4, 26-34, Metzler-Poeschel-Verlag
31. Walsh P (1997) The natural history of localized prostate cancer: a guide to therapy. In: Walsh P, Retik A, Stamey T, Vaughan EJ (eds) Campbell's Urology. 7th. ed. Saunders, Philadelphia, pp 2539-2564
32. Waterbor J, Bueschen A (1995) Prostate cancer screening (United States). Cancer Causes an Control 6: 267-274
33. Woodrum DL, Brawer MK, Partin AW, Catalona WJ, Southwick PC (1998) Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. J Urol 159: 5-12